CU23544A1 - Antígenos vacunales quiméricos contra el virus de la peste porcina clásica - Google Patents

Antígenos vacunales quiméricos contra el virus de la peste porcina clásica

Info

Publication number
CU23544A1
CU23544A1 CU20060052A CU20060052A CU23544A1 CU 23544 A1 CU23544 A1 CU 23544A1 CU 20060052 A CU20060052 A CU 20060052A CU 20060052 A CU20060052 A CU 20060052A CU 23544 A1 CU23544 A1 CU 23544A1
Authority
CU
Cuba
Prior art keywords
virus
chimeric
antigens
vaccine compositions
classical swine
Prior art date
Application number
CU20060052A
Other languages
English (en)
Inventor
Lepoureau Maria Teresa Frias
Carratala Yanet Prieto
Valle Maritza Isidra Barrera
Nordelo Carlos Guillermo Borroto
Baile Nancy Elena Figueroa
Ramos Oliberto Sanchez
Alonso Jorge Roberto Toledo
Molto Maria Pilar Rodriguez
Original Assignee
Ct Ingenieria Genetica Biotech
Ct Nac De Sanidad Agropecuaria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech, Ct Nac De Sanidad Agropecuaria filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20060052A priority Critical patent/CU23544A1/es
Priority to ARP070100808A priority patent/AR059648A1/es
Priority to CL2007000529A priority patent/CL2007000529A1/es
Priority to ES07711102T priority patent/ES2357563T3/es
Priority to EP07711102A priority patent/EP1994943B1/en
Priority to RU2008138536/10A priority patent/RU2406534C2/ru
Priority to DE602007011042T priority patent/DE602007011042D1/de
Priority to JP2008556644A priority patent/JP5190383B2/ja
Priority to CN201510530087.8A priority patent/CN105214081A/zh
Priority to CA2638830A priority patent/CA2638830C/en
Priority to CNA2007800146285A priority patent/CN101426525A/zh
Priority to AT07711102T priority patent/ATE490782T1/de
Priority to MX2008011144A priority patent/MX2008011144A/es
Priority to KR1020087023580A priority patent/KR101506979B1/ko
Priority to BRPI0708354A priority patent/BRPI0708354B1/pt
Priority to US12/280,055 priority patent/US8409562B2/en
Priority to PCT/CU2007/000008 priority patent/WO2007098717A2/es
Publication of CU23544A1 publication Critical patent/CU23544A1/es
Priority to HK16107128.2A priority patent/HK1219052A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Fiber Materials (AREA)

Abstract

La presente invención describe antígenos vacunales quiméricos contra el virus que causa la enfermedad de la Peste Porcina Clásica (VPPC). Dichos antígenos vacunales están basados en subunidades virales que están acopladas a moléculas proteicas estimuladoras del sistema inmune, tanto celular como humoral. Los antígenos quiméricos pueden ser producidos en sistemas de expresión que garantizan un correcto plegamiento tridimencional de las moléculas quiméricas que contituyen la base de la presente invención. Las composiciones vacunales que contienen dichos antígenos quiméricos inducen una respuesta inmune potente y temprana en los cerdos vacunados, confiriéndole una protección total contra el VPPC. Además las composiciones vacunales resultantes previenen la transmisión viral de las madres a su descendencia. Los antígenos quiméricos, así como las composiciones vacunales resultantes son aplicables a la esfera de la salud animal, como vacunas para uso preventivo en porcinos.
CU20060052A 2006-02-28 2006-02-28 Antígenos vacunales quiméricos contra el virus de la peste porcina clásica CU23544A1 (es)

Priority Applications (18)

Application Number Priority Date Filing Date Title
CU20060052A CU23544A1 (es) 2006-02-28 2006-02-28 Antígenos vacunales quiméricos contra el virus de la peste porcina clásica
ARP070100808A AR059648A1 (es) 2006-02-28 2007-02-27 Antigenos vacunales quimericos contra el virus de la peste porcina clasica
CL2007000529A CL2007000529A1 (es) 2006-02-28 2007-02-27 Antigeno vacunal quimerico contra el virus de la peste porcina clasica, vppc, que contiene el segmento extracelular de la glicoproteina e2 de la envoltura viral del vppc y una proteina estimuladora del sistema inmune cd154; composicion que lo comprende.
CA2638830A CA2638830C (en) 2006-02-28 2007-02-28 Chimeric vaccine antigens against classical swine fever virus
CNA2007800146285A CN101426525A (zh) 2006-02-28 2007-02-28 针对典型性猪瘟病毒的嵌合疫苗抗原
RU2008138536/10A RU2406534C2 (ru) 2006-02-28 2007-02-28 Химерные вакцинные антигены против вируса классической чумы свиней
DE602007011042T DE602007011042D1 (de) 2006-02-28 2007-02-28 Chimäre vakzine-antigene gegen das klassische schweinefieber-virus
JP2008556644A JP5190383B2 (ja) 2006-02-28 2007-02-28 ブタコレラウイルス（ｃｌａｓｓｉｃ ｓｗｉｎｅ ｆｅｖｅｒ）に対するキメラワクチン抗原
CN201510530087.8A CN105214081A (zh) 2006-02-28 2007-02-28 针对典型性猪瘟病毒的嵌合疫苗抗原
ES07711102T ES2357563T3 (es) 2006-02-28 2007-02-28 Antigenos quiméricos para vacunas contra el virus de la peste porcina clásica.
EP07711102A EP1994943B1 (en) 2006-02-28 2007-02-28 Chimeric vaccine antigens against classical swine fever virus
AT07711102T ATE490782T1 (de) 2006-02-28 2007-02-28 Chimäre vakzine-antigene gegen das klassische schweinefieber-virus
MX2008011144A MX2008011144A (es) 2006-02-28 2007-02-28 Antigenos vacunales quimericos contra el virus de la peste porcina clasica.
KR1020087023580A KR101506979B1 (ko) 2006-02-28 2007-02-28 전형적 돼지 콜레라 바이러스에 대한 키메릭 백신 항원
BRPI0708354A BRPI0708354B1 (pt) 2006-02-28 2007-02-28 antígeno vacinal quimérico contra o virús da peste suína clássica e composição de vacina capaz de produzir uma resposta imune protetora contra o vírus da peste suína clássica
US12/280,055 US8409562B2 (en) 2006-02-28 2007-02-28 Chimeric vaccine antigens against classical swine fever virus
PCT/CU2007/000008 WO2007098717A2 (es) 2006-02-28 2007-02-28 Antígenos vacunales quiméricos contra el virus de la peste porcina clásica
HK16107128.2A HK1219052A1 (zh) 2006-02-28 2016-06-21 針對典型性豬瘟病毒的嵌合疫苗抗原

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060052A CU23544A1 (es) 2006-02-28 2006-02-28 Antígenos vacunales quiméricos contra el virus de la peste porcina clásica

Publications (1)

Publication Number Publication Date
CU23544A1 true CU23544A1 (es) 2010-06-17

Family

ID=38279009

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20060052A CU23544A1 (es) 2006-02-28 2006-02-28 Antígenos vacunales quiméricos contra el virus de la peste porcina clásica

Country Status (17)

Country Link
US (1) US8409562B2 (es)
EP (1) EP1994943B1 (es)
JP (1) JP5190383B2 (es)
KR (1) KR101506979B1 (es)
CN (2) CN101426525A (es)
AR (1) AR059648A1 (es)
AT (1) ATE490782T1 (es)
BR (1) BRPI0708354B1 (es)
CA (1) CA2638830C (es)
CL (1) CL2007000529A1 (es)
CU (1) CU23544A1 (es)
DE (1) DE602007011042D1 (es)
ES (1) ES2357563T3 (es)
HK (1) HK1219052A1 (es)
MX (1) MX2008011144A (es)
RU (1) RU2406534C2 (es)
WO (1) WO2007098717A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI362416B (en) * 2008-07-31 2012-04-21 Mao Xing Biolog Technology Co Ltd Yeast expressed classical swine fever virus glycoprotein e2 and use thereof
CN103200961B (zh) 2009-03-27 2017-10-27 中央研究院 抗病毒免疫的方法和组合物
WO2017195919A1 (ko) * 2016-05-12 2017-11-16 주식회사 바이오앱 식물 유래의 돼지 열병 백신용 조성물 및 이의 제조방법
KR20210149121A (ko) * 2019-04-25 2021-12-08 애그리컬쳐럴 테크놀로지 리서치 인스티튜트 돼지열병 바이러스 감염 예방용 재조합 단백질 및 이를 포함하는 조성물과 세포
CU20210070A7 (es) * 2021-08-20 2023-03-07 Ct Ingenieria Genetica Biotecnologia Antígenos quiméricos para el control de coronavirus y composiciones que los comprenden
CN114835822B (zh) * 2022-04-22 2022-11-04 浙江洪晟生物科技股份有限公司 猪瘟病毒的多聚体疫苗及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
ZA901719B (en) 1989-03-19 1991-01-30 Akzo Nv Hog cholera virus vaccine and diagnostics
US5651972A (en) 1989-04-21 1997-07-29 University Of Florida Research Foundation, Inc. Use of recombinant swine poxvirus as a live vaccine vector
EP0924298A1 (en) 1997-12-18 1999-06-23 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Protein expression in baculovirus vector expression systems
FR2804028B1 (fr) 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
WO2001083737A2 (en) 2000-05-03 2001-11-08 University Of Guelph Porcine adenovirus type 5 vector and vaccine
RU2183972C2 (ru) 2000-07-13 2002-06-27 ВНИИ ветеринарной вирусологии и микробиологии Способ получения высокоактивной специфической к вирусу классической чумы свиней сыворотки крови свиней
CN1338309A (zh) 2000-08-10 2002-03-06 清华大学 一种合成肽猪瘟疫苗及其制备方法
RU2182495C1 (ru) 2001-05-03 2002-05-20 Федеральное государственное учреждение Всероссийский научно-исследовательский институт защиты животных Вирусвакцина против классической чумы свиней
US20040096457A1 (en) * 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
CU23102A1 (es) 2002-10-21 2005-12-20 Ct Ingenieria Genetica Biotech Método para la producción de proteínas recombinantes en la glándula mamaria de mamíferos no transgénicos
US7183384B2 (en) * 2003-03-06 2007-02-27 A & G Pharmaceutical, Inc. Monoclonal antibody 7H11 reactive with human cancer
EP1522585A1 (en) * 2003-10-09 2005-04-13 Plant Research International B.V. Chimeric carrier molecules for the production of mucosal vaccines

Also Published As

Publication number Publication date
WO2007098717A2 (es) 2007-09-07
CN105214081A (zh) 2016-01-06
ATE490782T1 (de) 2010-12-15
CN101426525A (zh) 2009-05-06
AR059648A1 (es) 2008-04-16
BRPI0708354B1 (pt) 2016-04-19
MX2008011144A (es) 2009-01-26
KR20080111023A (ko) 2008-12-22
JP2009528304A (ja) 2009-08-06
CA2638830C (en) 2015-04-14
JP5190383B2 (ja) 2013-04-24
EP1994943B1 (en) 2010-12-08
EP1994943A2 (en) 2008-11-26
BRPI0708354A2 (pt) 2011-05-24
KR101506979B1 (ko) 2015-03-30
HK1219052A1 (zh) 2017-03-24
DE602007011042D1 (de) 2011-01-20
RU2406534C2 (ru) 2010-12-20
CA2638830A1 (en) 2007-09-07
RU2008138536A (ru) 2010-04-10
ES2357563T3 (es) 2011-04-27
CL2007000529A1 (es) 2008-01-18
US8409562B2 (en) 2013-04-02
US20090304633A1 (en) 2009-12-10
WO2007098717A3 (es) 2007-11-01

Similar Documents

Publication Publication Date Title
CU23576A1 (es) Antígenos vacunales quiméricos contra el virus de la influenza aviar
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CY1113546T1 (el) Μικρορευστοποιημενα γαλακτωματα ελαιου σε νερο και συνθεσεις εμβολιων
CU23544A1 (es) Antígenos vacunales quiméricos contra el virus de la peste porcina clásica
ECSP077888A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
CR10559A (es) Vacuna de influenza
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
AR060565A1 (es) Vacuna para la gripe aviaria y metodos de uso
CR11122A (es) Vacuna de influenza de emulsion de aceite en agua
TW200806316A (en) Yeast-based vaccine for inducing an immune response
MX2009006178A (es) Vacuna contra salmonela.
MX2008013619A (es) Aumento del titulo para vacunacion en animales.
CY1113540T1 (el) Εμβολια γριππης σκυλων
EA201891124A2 (ru) Новые мукозные адъюванты и системы доставки
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
WO2009077577A3 (en) Vaccine antigens from piscirickettsia salmonis
BR112016002354A2 (pt) composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
ATE526034T1 (de) Verbesserte inaktivierte fcv-vakzinen
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων
NZ599219A (en) Adjuvanted vaccine formulations
AR065765A1 (es) Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus

Legal Events

Date Code Title Description
FG Grant of patent